Cerepro: instructions for use (400 mg capsules)

pharmachologic effect

The active substance of the drug is glycerylphosphorylcholine hydrate. Due to the enzymatic breakdown of this substance, choline and glycerophosphate are delivered to the cells of the body. Choline is a substrate for the synthesis of acetylcholine, while glycerophosphate ensures the synthesis of phosphatidylcholine in neuronal membranes. As a result, in the body, under the influence of the drug, metabolic processes and blood flow in the central nervous system are activated, synaptic transmission is improved, and cholinergic activity is reduced. The drug improves plasticity and restores the integrity of previously damaged neuronal membranes at the cellular level.

As a result, the use of the drug improves cognitive and behavioral reactions, normalizes brain activity, and involution of the psychoorganic syndrome is noted in people experiencing a post-traumatic period, as well as in those who have problems with cerebral vessels. The drug also normalizes spatiotemporal characteristics during spontaneous brain activity. Cerepro does not affect reproductive function and does not have mutagenic or tetragenic effects.

Cerepro

Name: Cerepro Pharmacological action: Glycerylphosphorylcholine hydrate is the active ingredient of the drug Cerepro. The enzymatic breakdown of this substance leads to the delivery of choline and glycerophosphate to the cells. Choline is a substrate for the synthesis of acetylcholine, glycerophosphate is for the synthesis of phosphotidylcholine in neuronal membranes.

By increasing the synthesis of acetylcholine and components of cell membranes, there is an increase in metabolism and blood flow in the central nervous system, a decrease in cholinergic activity, and an improvement in synaptic transmission. At the cellular level, there is an increase in plasticity and restoration of the integrity of damaged neuronal membranes. The result of taking Cerepro is an improvement in behavioral and cognitive reactions, normalization of bioelectrical activity of the brain, involution of the psychoorganic syndrome in patients in the post-traumatic period and with vascular pathologies of the brain

Indications for use: Cerepro is indicated for the following pathological conditions: - acute period after TBI (traumatic brain injury); - recovery period after head injuries; - acute period of ischemic stroke; — post-stroke period (after ischemic stroke); - post-stroke period with focal symptoms, with signs of damage to the brain stem after a hemorrhagic stroke - degenerative, involutional changes in the brain with psychoorganic symptoms; - cerebrovascular insufficiency; - senile pseudomelancholy; - dementia; — encephalopathy; - cognitive disorders; - cerebrovascular disease; - disorientation; - demoralization; - intracranial injury; - consequences of intracranial injury; - apathy.

Method of administration: Acute conditions: administration intramuscularly, intravenously, daily dose – 1 g. The course of treatment with the parenteral form is 10-15 days, then prescribed orally for another 6 months at a dosage of 1200 mg/day. Capsules are not prescribed for use in the evening, as this can cause overexcitement and insomnia. The oral dose is distributed over the morning and lunchtime (800 mg in the morning, 400 mg in the afternoon), taken before meals. If well tolerated, Cerepro can be prescribed 400 mg x 3 times. For chronic conditions, start with the oral form in a standard dosage (1200 mg/day).

Side effects: Taking Cerepro may be accompanied by undesirable reactions: - nausea; - allergic manifestations; - gastritis; - dyspepsia; - peptic ulcer; - dryness of the oral mucosa; - pharyngitis; - anxiety states; - insomnia; — aggressiveness; - nervousness; - headache; - drowsiness; - hyperkinesia; - convulsive reactions; - dizziness; - frequent urination; - urticaria; - pain when inserted into a muscle or vein; - post-injection local pain.

Contraindications: Cerepro is not prescribed for: - acute stage of hemorrhagic brain damage; - pregnancy; - lactation; - hypersensitivity to components. Cerepro is not indicated in pediatric practice.

Pregnancy: Cerepro should not be used by pregnant women.

Interaction with other drugs: Cerepro and other drugs when used together did not have significant interactions.

Overdose: Exceeding the dose of Cerepro may be accompanied by dyspepsia and increased side effects. Treatment is symptomatic.

Release form: Cerepro is available in ampoules (1000 mg/4 ml) and tablets (400 mg). The tablets are packaged as follows: - blister of 10 pcs; — jar of 10 pcs; — blister of 14 pcs; - jar of 14 pcs.

The packaging of ampoules in contour packages (cell and cellless) is as follows: 3 and 5 amps. (one contour pack in a pack), 10 amp. (two contour packs of 5 ampoules per pack).

Storage conditions: Storage temperature of the drug Cerepro is up to 25 degrees Celsius. Ampoules and tablets, when properly stored, have a shelf life of 2 years.

Synonyms: Gleatser, Gliatilin, Glycerylphosphorylcholine hydrate, Delecite, Noocholine, Fosal GPC, Choline alfoscerate hydrate, Choline alfoscerate, Holitylin, Cereton.

Composition: 1 capsule of Cerepro contains glycerylphosphorylcholine hydrate 0.4 g. Auxiliary components: glycerin, gelatin, prepared water, methylparaben, propylparaben, sorbitol, red iron oxide (dye), titanium dioxide.

1 ampoule of Cerepro contains glycerylphosphorylcholine hydrate 1000 mg. Auxiliary component: water.

Additionally: If you experience nausea while taking Cerepro, the dose may be reduced. Cerepro does not affect the speed of psychomotor reactions, but side effects such as dizziness or asthenia may become an obstacle to driving vehicles and performing certain types of work.

Attention! The description of the drug " Cerepro " on this page is a simplified and expanded version of the official instructions for use. Before purchasing or using the drug, you should consult your doctor and read the instructions approved by the manufacturer. Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.

Indications for use of Cerepro

Indications for use of Cerepro are as follows:

• consequences of traumatic brain injury (acute period);
• recovery from head injuries;
• acute period after an ischemic stroke ;
• post-stroke period after a hemorrhagic stroke, in which focal symptoms are present, and there are also symptoms of brain stem damage;
• involutional and degenerative changes in the brain, in which psychoorganic symptoms are noted;
• lack of blood flow in the brain;
• dementia;
• senile pseudomelancholia;
• encephalopathy;
• cognitive disorders;
• manifestation of cerebrovascular disease;
• disorientation;
• state of demoralization, apathy;
• intracranial injury and its consequences.

Indications

There are many indications for using Cerepro:

• Acute and recovery periods of TBI, especially severe, as well as ischemic stroke.
• The recovery period after a hemorrhagic stroke with focal hemispheric symptoms or manifested by damage to the trunk.
• Psychoorganic syndrome in involutive and degenerative processes.
• Encephalopathy.
• Cognitive impairment, including memory loss, confusion, disorientation, loss of motivation, decreased concentration, and more, up to dementia with encephalopathies.
• Age-related pseudomelancholia.

Side effects

When treated with this drug, the patient may experience some adverse reactions:

• allergic reactions;
• dyspepsia;
• symptoms of gastritis;
• peptic ulcer;
• feeling of dryness of the oral mucosa;
• pharyngitis;
• state of aggressiveness, anxiety, sleep problems;
• dizziness , headache;
• hyperkinesia;
• convulsions;
• frequent urination.

When the drug is administered, the patient may feel pain, and post-injection local pain may also occur.

Instructions for use of Cerepro (Method and dosage)

If a patient is prescribed Cerepro for acute conditions, the instructions for use stipulate that the injections are administered intramuscularly or intravenously, the dose being 1 g per day.

The drug in parenteral form is prescribed for 10-15 days, after which the patient must also take the oral form of Cerepro for 6 months. In this case, the daily dose of the drug is 1200 mg.

The instructions for use of Cerepro include a note that the capsules should not be taken in the evening, as this may lead to sleep problems.

It is advisable to take capsules in the morning (800 mg) and at lunchtime (400 mg). The product should be taken before meals. If the drug is well tolerated by the patient, it can be prescribed three times, 400 mg each. If the patient has a chronic condition, treatment begins with taking capsules, and the dosage is 1200 mg/day.

Cerebrovascular diseases and their most severe forms—acute cerebrovascular accidents (ACVA)—are the most important medical and social problem [3, 12]. Vascular diseases of the brain have taken 2nd place in Russia (after cardiovascular diseases) among all causes of death in the population [2, 12]. Registry data show that about 450,000 strokes occur annually in Russia, with a mortality rate reaching 35% [2]. In Moscow alone, the number of patients with ischemic stroke was 26,608 in 2009, 28,653 in 2010. During the period from 1990 to 2010, there was an increase in the mortality rate from cerebrovascular diseases by 18.5% [2]. Among diseases of the nervous system that lead to permanent disability, cerebrovascular disorders occupy 1st place [2, 3, 12]. This dictates the need to strengthen efforts to prevent strokes and chronic progressive vascular diseases of the brain.

In the pathogenesis of vascular lesions of the brain, the leading role is given to the processes of ischemia, excitotoxicity and apoptosis, excessive activation of the glutamatergic system on the one hand, insufficient activity of the cholinergic and GABAergic systems on the other [3, 4, 11]. Based on the characteristics of pathogenesis, pharmacological agents that affect neurotransmitter systems have been widely used in the treatment of patients with acute and chronic vascular diseases of the brain. Considerable experience has been accumulated in influencing dopaminergic (L-DOPA drugs), glutamatergic (racetams, memantine), GABAergic and cholinergic receptor formations. It must be said that the cholinergic system, widely represented in various parts of the central nervous system (CNS), closely interacting with dopamine, GABA and glutamatergic systems, ensures spontaneous activity, emotional behavior, memory and volitional acts. In this regard, the effect on the cholinergic apparatus has always been one of the important tasks in the treatment of cerebrovascular diseases [1, 3, 4, 8-10].

Among the drugs with a central cholinomimetic effect is choline alfoscerate. By participating in the synthesis of acetylcholine, the drug has a positive effect on neurotransmission. Glycerophosphate contained in choline alphoscerate is a precursor of membrane phospholipids and myelin, therefore the drug improves membrane plasticity, receptor function and synaptic transmission. While taking it, an increase in blood flow and metabolic processes in the central nervous system is shown. Choline alfoscerate activates the reticular formation and helps normalize the spatiotemporal characteristics of spontaneous bioelectrical activity of the brain. In general, choline alfoscerate has a distinct nootropic effect, has a neuroprotective effect, activating an effect on brain structures, improves cognitive functions, attention, memorization and reproduction of information [1, 6, 7].

Choline alfoscerate preparations are currently effectively used in the treatment of a number of neurological and borderline psychiatric diseases: chronic cerebral ischemia, cognitive impairment of various etiologies, consequences of traumatic brain injuries, asthenia and chronic fatigue syndrome [5-7].

The purpose of this study was to evaluate the clinical efficacy and tolerability of the drug choline alfoscerate, Cerepro, in the treatment of patients with cerebrovascular diseases in an outpatient setting.

Material and methods

The study included 90 patients aged from 45 to 80 years (average - 62.34±5.7 years) with chronic progressive vascular diseases of the brain, undergoing rehabilitation in the district neurological departments of Moscow. Of these, 60 (66.7%) patients suffered a cerebral infarction, the remaining 30 (33.3%) patients were diagnosed with chronic cerebral ischemia (CHI).

The exclusion criteria from the study were: the presence of severe motor, speech, and cognitive deficits; severe, decompensated or unstable somatic diseases; tumors of various localizations; endogenous mental illnesses.

During a neurological examination, the majority of patients revealed coordination (77.7%), sensory (64.4%) and motor disorders in the form of moderate hemiparesis (34.0%). Elements of motor aphasia were noted in 10 patients, sensory aphasia in 2, mixed aphasia in 3. Cognitive changes were observed in 62 (68.9%) patients with an average score on the MMSE scale of 24.7±0.5 points.

Arterial hypertension was observed in more than half of the patients - in 57 (63.3%), coronary heart disease was detected in 30 (33.3%). 24 (26.7%) patients had other concomitant somatic diseases: urolithiasis, chronic cholecystitis, chronic gastritis, chronic bronchitis, spastic colitis, chronic pyelonephritis.

Of the patients who suffered a stroke, 24 (40.0%) suffered a heart attack in the territory of the right middle cerebral artery, 28 (46.7%) of the left middle cerebral artery, and 8 (13.3%) patients in the vertebrobasilar territory. The duration of the stroke ranged from 60 to 274 days (on average 158±10.6 days); patients predominated (71.2%) with a history of acute stroke of 4-6 months.

Using computer (CT) or magnetic resonance (MRI) imaging of the brain, signs of a heart attack were recorded in 57 (63.3%) of the examined patients; in 26 (28.9%) patients, multiple foci of vascular origin were identified in the brain substance , phenomena of leukoaraiosis and hydrocephalus. In 7 patients, no changes were detected during neuroimaging.

All patients, along with basic drugs (antihypertensives, antiplatelet agents or anticoagulants, hypocholesterolemic drugs), were prescribed intravenous drip administration of Cerepro 1000 mg per day per 200 ml of saline solution for 10 days (with a 2-day break on Saturday and Sunday) followed by oral administration the drug in a daily dose of 1200 mg (1 capsule 3 times a day) for 6 weeks. During the study, the use of other nootropic and neurometabolic drugs was prohibited.

To differentiate the effectiveness of therapy, all patients included in the study were divided into 2 groups: group 1 consisted of 60 patients in the recovery period of ischemic stroke; 2nd - 30 patients with CCI. In terms of age and gender composition and a number of clinical characteristics, the groups were statistically homogeneous and comparable.

To assess the effectiveness of therapy, the dynamics of neurological symptoms was studied. Additional methods were also used: scoring the subjective severity of neurological symptoms; brief scale for assessing higher mental functions MMSE (Mini-Mental State Examination); methodology for rapid assessment of well-being, activity and mood (SAM); Hamilton Depression Scale; Clinical Global Impression (CGI) scale; scoring of the tolerability and effectiveness of the drug (0-5 points). Neurological status, state of mental functions according to the MMSE scale, subjective severity of neurological symptoms (in points), indicators using the SAN method and the Hamilton test were assessed before the start of therapy (1st visit), after 10 days of parenteral administration of the drug (2nd visit) and after completion of the treatment course (3rd visit). Patients were assessed using the CGI scale at visits 1 and 3. The severity of the therapeutic response and drug tolerability were determined within each group.

The results were entered into the patient’s individual protocol and further statistically processed using Excel, Epi and Statistica 6.0 programs. The significance of the differences was determined using the parametric method (Student's t-test) and nonparametric statistics (criterion &khgr;2). Differences were considered statistically significant at p<0.05.

results

In patients of group 1 who suffered a stroke, when assessing the neurological status after completing the course of treatment with Cerepro, a decrease in the degree of paresis and regression of sensory disorders were noted, but these changes did not reach the level of statistical significance. At the same time, there was a significant (p = 0.036) decrease in the severity of coordination disorders.

A statistically significant (p<0.05) improvement was observed when assessing mental functions on the MMSE scale. Initially, disturbances in orientation, perception, speech, writing and reading in the examined patients using the MMSE scale corresponded to mild dementia (average score - 23.8±0.65). During Cerepro therapy, the overall test score increased, reaching the level of mild cognitive impairment by the end of the study - 25.0±0.81 points.

Subjectively, all examined patients noted a decrease in affective tone, up to the development in some cases of depressive manifestations, and somatovegetative and cerebrasthenic disorders were identified. Along with a decreased background mood, depression, internal tension, restlessness, and anxiety, most patients also showed a decrease in the productivity and focus of intellectual activity, impaired concentration of active attention, and a low level of activity and motivation. The use of the SAN technique made it possible to state a significant (p<0.05) decrease in the severity of emotional and autonomic disorders in patients in this group after 8 weeks of Cerepro therapy.

Upon admission to treatment, 41 (68.3%) patients showed depressive symptoms on the Hamilton scale; in the remaining patients they did not reach the clinically defined level. By the time of completion of therapy with the drug Cerepro, mild depressive symptoms on the Hamilton scale were detected in only 46.6% of patients; the remaining patients did not present any complaints from the depressive register during testing. However, there was no statistically significant change in the Hamilton Depression Scale score in this group of patients by the end of the study.

When assessed on the CGI scale, regression of objective signs of cognitive and focal impairments was revealed: the total score increased in the study group from the level of moderate deficit to mild.

The use of a score for the subjective severity of neurological symptoms made it possible to state a significant (p<0.05) decrease in the degree of emotional disorders in patients of group 1. At the 1st visit, most patients presented asthenic complaints of severe general weakness, fatigue, and impaired concentration. After 8 weeks of therapy with Cerepro, a significant proportion (p<0.05) of patients noted a decrease in asthenia and fatigue. A significant (p <0.05) effect of Cerepro on somatovegetative manifestations was also found - the intensity of headache and the severity of dizziness (Table 1).

In patients of group 2 with CCI, a study of the neurological status revealed a gradual regression of sensory and coordination disorders, but the severity of the changes did not reach the level of statistical significance.

When assessing the neuropsychological status at the end of treatment with Cerepro, a statistically significant improvement was observed in most parameters of the MMSE scale. The positive effect of the drug was established in terms of attention, memory and counting (p<0.05). The total score of the MMSE scale at the time of completion of the study corresponded to the level of mild cognitive impairment - 27.1±0.8 (at the 1st visit - 25.0±0.66 points, p<0.05).

By the end of the course of treatment with Cerepro, all patients in this group showed a general improvement in well-being, increased daily activity, and improved mood. A significant (p<0.05) improvement in indicators of well-being, activity and mood on the SAN scale, a decrease in the severity of asthenic manifestations, an increase in affective tone and the level of daily activity were recorded.

Before the start of the study, depressive symptoms of varying severity when assessed on the Hamilton scale were identified in 18 (60%) patients. By the end of the study, positive changes on the Hamilton scale were noted in 13 patients. In 4 cases, after 2 months of therapy with Cerepro, only slight or minimal improvement was noted, and in 1 case, depressive disorder remained stable in its manifestations. There were no significant differences in the average group score on this scale before and after treatment.

After 8 weeks of therapy with Cerepro, the score on the CGI scale changed significantly (p<0.05) - the total score for the severity of disorders decreased to the level of mild severity.

Improvement in the condition of patients in group 2 with CCI was also observed on the scale of subjective disorders. After 8 weeks of using Cerepro, patients noted positive changes in well-being, a decrease in the severity of depression, general weakness, and fatigue. Statistically significant (p<0.05) changes concerned memory indicators, asthenic manifestations and dizziness (Table 2).

A comparative analysis of the dynamics of the neurological status in patients of the 1st and 2nd groups showed a decrease in the degree of paresis in patients of the 1st group and a gradual regression of sensory and coordination disorders in patients of both groups by the 8th week of Cerepro therapy, however, no significant differences were observed between groups . Upon completion of the course of treatment, an increase in the total score on the MMSE scale was revealed in patients of both groups to the level of mild cognitive impairment. Similarly, there was an increase in scores on three components of the SAN scale (well-being, activity, mood) with a simultaneous decrease in the severity of depression on the Hamilton scale and a decrease in the severity of disorders on the CGI scale. There were no statistically significant differences in the results of the study of cognitive and psychoemotional status in patients of both groups (Table 3).

By the time the study was completed, overall therapeutic efficacy of varying severity was observed in all patients included in the study (100%), including a very good result in 15 (16.7%), good in 64 (71.1%) and satisfactory - in 11 (12.2%). In a comparative analysis by group, clinical effectiveness turned out to be higher in the treatment of patients in group 1 due to a significant reduction in the degree of coordination and cognitive disorders (Table 4).

There were no statistically significant differences in the tolerability of the drug in patients of both groups. In most cases - in 69 (76.7%) patients - tolerability was rated as good or very good (see Table 4). No significant side effects in the form of deterioration in somatic condition and mental status were registered in the studied patients. In 5 patients (5.5%, 4 patients of the 1st group and 1 patient of the 2nd group) during intravenous drip administration of the drug, headache and an increase in blood pressure above the adaptation figures were noted. Slower intravenous administration of the drug over 1 hour neutralized the increase in blood pressure.

When taking Cerepro orally, 8 patients (8.8%, 3 patients of group 1 and 5 patients of group 2) experienced headache (2 cases) and nausea (2 cases) in the first 2 weeks of taking the drug. These complaints did not require additional treatment or discontinuation of the drug. Another 3 patients experienced anxiety and agitation while taking Cerepro; 1 patient complained of sleep disturbances and difficulty falling asleep. In these cases, it was recommended to take the drug before 18 hours; specific therapy was not prescribed.

Among the variety of pharmacological agents used in neurological practice, one of the most popular in the treatment of vascular diseases of the brain are cholinergic drugs, in particular choline alfoscerate. The effectiveness of the drug in the treatment of acute and chronic cerebral circulatory failure, post-traumatic and toxic encephalopathy, degenerative diseases of the central nervous system, and complex therapy of Alzheimer's type dementia has been confirmed in many studies [5-7].

The present study revealed a distinct nootropic effect of choline alfoscerate (Cerepro). Cognitive functions significantly improved with the use of the drug: attention, memorization and reproduction of information. A reliable complex effect of Cerepro on asthenic syndrome and low mood was also revealed. However, no significant effect of the drug on focal neurological symptoms in patients with vascular diseases of the brain was found. A clinically significant reduction in cognitive and emotional disorders, along with an improvement in the well-being of patients, was evident by the 8th week of continuous use of the drug. There were no serious complications or side effects that required additional measures during treatment with Cerepro.

Thus, the study demonstrated the effectiveness of Cerepro in the treatment of patients with vascular diseases of the brain, including during the recovery period of ischemic stroke. The drug can be recommended for use in complex therapy of patients with vascular diseases of the brain at the stage of outpatient rehabilitation.

Analogues of Cerepro

Level 4 ATC code matches:
Delecite

Choline alphoscerate

Cereton

Gliatilin

Pharmacies sell both more expensive and cheaper analogues of Cerepro. These are the following drugs: Noocholin Rompharm , Gliacer , Glycerylphosphorylcholine hydrate , Gliatilin , Fosal , Cholitilin , Choline alfoscerate hydrate , Cereton , Delecite .

Gliatilin or Cerepro: which is better?

Both of these products contain a similar active ingredient. They are distinguished only by price and quality level. Cerepro is a cheaper drug, but the level of purity of the active substance in it is lower, therefore, the effect on the body may be less pronounced.

Reviews of Cerepro

Those patients who have used Cerepro for treatment leave mostly positive reviews on the forums. Reviews from doctors also indicate that this drug is highly effective for a variety of brain pathologies. Side effects during treatment with this drug are rare, so Cerepro is well tolerated and is often used for long-term therapy. The drug is used for children only in cases where the appropriateness of the prescription is confirmed by a doctor. Reviews note a pronounced positive effect of drugs in the treatment of children.

Cerepro capsules 400 mg No. 14x1

Name

Cerepro.

Description

The capsules are soft gelatin, oblong, red to brown in color.

Main active ingredient

Choline alfoscerate.

Release form

Capsules.

Dosage

400 mg.

pharmachologic effect

Pharmacodynamics

Choline alphoscerate is a transport form of choline and a precursor of phosphatidylcholine, which has the potential to prevent membrane damage as one of the factors in the pathogenesis of psychoorganic involution syndrome, characterized by a decrease in cholinergic synaptic transmission and damage to the phospholipid composition of neuronal membranes. The chemical structure of choline alfoscerate (containing 40.5% choline) and the associated physicochemical properties of the molecule ensure that part of the choline penetrates the blood-brain barrier. The results of preclinical and clinical studies confirm the ability of choline alfoscerate to influence primarily cognitive-mnestic functions, as well as emotional and behavioral activity, impaired in involutional pathology of the brain.

Pharmacokinetics

The pharmacokinetic characteristics of the radiolabeled drug when administered were similar in different animal species (rats, dogs, monkeys) and gave the following results: rapid and complete absorption in the gastrointestinal tract, distribution of choline and its metabolites in various organs and tissues, including the brain , renal excretion was approximately 10% of the administered dose after 96 hours; the content of the drug in brain tissue is higher compared to tritium-labeled choline.

Indications for use

Psychoorganic syndrome due to involutional and degenerative processes in the brain; consequences of cerebrovascular insufficiency, such as primary and secondary cognitive impairment in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and ability to concentrate. Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest.

Directions for use and doses

The recommended dose is 1 capsule 2-3 times a day before meals. If necessary, the dosage can be increased on the recommendation of the attending physician. The duration of the course of treatment is determined by the doctor taking into account the disease, tolerability of the drug and the achieved effect.

Use during pregnancy and lactation

The use of the drug Cerepro during pregnancy and lactation (breastfeeding) is contraindicated.

Precautionary measures

If there is no improvement, worsening of the condition, or if additional questions arise, you should consult a doctor. The medicinal product contains sorbitol, a non-crystallizing solution. Therefore, the drug should not be taken by patients with hereditary fructose intolerance. Due to the glycerin content, this medicine may cause headaches, stomach upset and diarrhea (diarrhoea). Since the drug contains methyl parahydroxybenzoate E-218 and propyl parahydroxybenzoate E-216, allergic reactions (including delayed ones) are possible. Use in children The medicinal product is not intended for use in children under 18 years of age. There is no experience with the use of Cerepro in children.

Interaction with other drugs

Drug interactions with Cerepro have not been established.

Contraindications

pregnancy; lactation period; children's age (up to 18 years); hypersensitivity to the components of the drug.

Compound

One capsule contains: glycerylphosphorylcholine hydrate (choline alfoscerate) - 400.0 mg. Excipients: glycerin, purified water. Composition of the capsule shell: gelatin, glycerin, sorbitol non-crystallizing solution, purified water, methyl parahydroxybenzoate E-218, propyl parahydroxybenzoate E-216, titanium dioxide E-171, red iron oxide E-172.

Overdose

Symptoms: nausea. If this symptom appears, it is recommended to reduce the dose of the drug. In case of overdose, symptomatic therapy is indicated. The effectiveness of dialysis has not been established.

Side effect

Nausea (due to dopaminergic activation), in this case the dose of the drug should be reduced. Allergic reactions are possible. Very rarely, abdominal pain and short-term confusion are possible. If any adverse reactions occur, including those not listed in these instructions, you should consult a doctor.

Storage conditions

Store in a place protected from moisture and light at a temperature not exceeding 25 °C. Store out of the reach of children.

Buy Cerepro caps.400 mg in container pack No. 14x1 in the pharmacy

Price for Cerepro caps. 400 mg in container pack No. 14x1

Instructions for use for Cerepro caps. 400 mg in container pack No. 14x1